The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.875
Bid: 9.50
Ask: 10.25
Change: 0.175 (1.80%)
Spread: 0.75 (7.895%)
Open: 9.875
High: 9.875
Low: 9.875
Prev. Close: 9.70
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS: Miners Jump On Upbeat Chinese Data

Mon, 02nd Jun 2014 10:39

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Monday.
-------
FTSE 100 - WINNERS
-------
Anglo American, up 1.9%, Rio Tinto, up 1.7%, Glencore, up 1.4%, BHP Billiton, up 0.8%. The mining stocks are all big gainers after a gauge of China's factory activity rose to a five-month high in May, suggesting the world's second-largest economy is stabilizing after a subdued start to the year. The official purchasing managers' index improved to 50.8, from 50.4 in April, its third straight month of improvement.

Shire, up 1.3%. The pharmaceutical company has secured a USD5 billion credit facility from banks including Citigroup to finance a takeover offer for the US's NPS Pharmaceuticals, The Times said on Monday, citing insiders. It is believed to have arranged the deal to buttress its takeover offer for NPS, a developer of drugs for sufferers of a debilitating bowel condition.
-------
FTSE 100 - LOSERS
-------
Standard Life, down 2.6%. The long-term savings and investments provider is the biggest faller in the blue-chip index following reports in the weekend press that the pension industry will see a further shake up during the Queen's Speech on Wednesday. "It is thought that the Queen's Speech on Wednesday will include news that UK workers will be offered 'collective pension schemes' by 2016, delivering efficiency for the saver, but which would evidently prove less lucrative for providers at a time when opaque financial charging structures are under the microscope," says Michael van Dulken, head of research at Accendo Markets.

Smith & Nephew, down 1.8%. The medical technology company has fallen sharply following a strong share price run, which saw it close the last three trading sessions as the FTSE 100's biggest riser. The group jumped 9.8% in three days after the Financial Times published an article on Wednesday that suggested that Stryker, a US maker of hip implants and knee replacements, was about to make an unquantified takeover bid for the company. While Stryker quickly denied the rumours, Smith & Nephew's shares still benefited from the speculation.

GlaxoSmithKline, down 0.5%. UK-based biotechnology company Adaptimmune Ltd has confirmed that it has entered into a collaboration and licensing agreement with pharmaceutical giant GlaxoSmithKline worth a potential USD350 million over the next seven years, for its cancer programme. Under the agreement, the two companies will develop and commercialise Adaptimmune's NY-ESO-1 cancer treatment, as well as Adaptimmune's other treatments using its T-cell receptor engineering technology. Separately, on Sunday, Glaxo announced that a late stage study of its two anti-HER2 agents lapatinib and trastuzumab did not meet their primary endpoint of improved disease free survival compared to a treatment of just trastuzumab for HER2 positive early breast cancer.
-------
FTSE 250 - WINNERS
-------
St Modwen Properties, up 2.7%. The property company said it still expects to report pretax profit for the first half of its financial year significantly up on the year-earlier period, after it continued to perform "strongly" over the past two months. It said it expects its asset management and added value activities to be reflected positively in half-year valuations, while initial indications point to a rise in market valuations for the first half of the year compared with November 2013, reflecting improvements in the residential and commercial property markets across the UK.

Man Group, up 2.5%. Berenberg has upgraded the hedge fund manager to Hold, from Sell, increasing its target price to 90.00 pence, from 70.00p. After an enormous restructuring effort over the last three years, Man Group looks to be turning a corner as legacy issues associated with its quantitative fund management arm, AHL, are set to gradually ease, said Berenberg analyst Pras Jeyanandhan.
-------
FTSE 250 - LOSERS
-------
Fenner, down 2.8%. The polymer products maker's shares are among the biggest fallers in the mid-cap index for a second day in a row, having dropped 10% on Friday, after it said on Friday that its underlying pretax profit for the current financial year will come in 10% to 15% below the consensus estimate of GBP77.6 million. Liberum Capital has cut its target price on the company to 345.00 pence from 445.00p Monday, following the warning.
-------
AIM ALL-SHARE - WINNERS
-------
Bglobal, up 60%. The company said it had agreed to sell its Utiligroup Ltd subsidiary for GBP16.1 million in cash to private equity company NorthEdge Capital LLP, and plans to return money to shareholders and de-list from AIM once the deal completes. Bglobal said the deal will have to be approved by its shareholders. It said it expects to have cash balances of GBP16.8 million after the deal completes, and is already talking with its advisors about the most effective way of returning this money to its shareholders.

Union Jack Oil, up 42%. The oil and gas exploration and development company said that an independent technical report carried out on its PEDL201 licence in the UK Midlands has confirmed significant shale oil and gas potential at the Widmerpool Gulf region of the site. It said the report has shown mean gross unrisked estimates of 5.4 billion barrels of oil and over 2.7 trillion standard cubic feet of gas in the region.

Leni Gas & Oil, up 30%. The oil and gas exploration and development company said its GY-664 well in the Goudron Field, Trinidad, was brought into production on Friday and has now stabilised at a strong rate of 240 barrels of oil per day, while drilling at its GY-665 well has already found a region of oil-bearing sand. The GY-664 well has achieved a stabilised rate four-times above production assumptions of 60 barrels of oil per day based on historical data from the field. The group also announced that its second development well at the site, GY-665, has now drilled to 1,606 feet on its way to a total depth of 3,500 feet, and it has already intersected a 310 feet region of gross oil sand in the Goudron sandstones formation of the site.

Range Resources, up 23%. The hydrocarbon exploration firm said it has entered into a services agreement with LandOcean Energy Services Co Ltd, coupled with a financing package of USD50 million. It said that as part of a master services agreement, LandOcean will be the preferred services contractor for Range's oilfield services, including geoscience, engineering, procurement and construction. The company said services provided under the deal will be agreed on an individual basis and where services have led to increased production, LandOcean will be entitled to an incremental production bonus share of its costs and capital expenditure. It said the deal will last eight years and could cover a total contract value of up to USD400 million. Range Resources also said that in addition to the agreement, LandOcean will provide the company with an option to take up to USD50 million in financing, primarily for LandOcean's services.

Tanfield Group, up 7.7%. The investment company said it swung to a pretax profit in 2013 due to positive adjustments in the fair value of its investments, and it outlined a new investment strategy and detailed plans to raise money to acquire and fund new investments in the technology sector. It said it made a GBP7.4 million pretax profit in 2013, compared with a GBP13.4 million pretax loss in 2012. Revenue fell to GBP2.2 million, from GBP3.3 million, while staff costs and other operating expenses fell to GBP3.3 million, from GBP4.6 million.

Scancell Holdings, up 6.5%. The cancer treatment developer said the latest results from a trial of its SCIB1 ImmunoBodyÒ treatment on skin cancer had shown further evidence of tumour reduction and disease control, enhanced immune responses and "highly encouraging" survival times. It said the latest result from the continuing phase 1/2 clinical trial in patients with Stage III/IV melanoma also showed that SCIB1 is safe and well-tolerated.
-------
AIM ALL-SHARE - LOSERS
-------
DQ Entertainment, off 27%. The animation, gaming, live action, and entertainment production and distribution company reported higher profit for its last financial year as revenue was lifted by distribution deals as the company tapped new markets in Latin America, Africa, South East Asia and the Middle East. However, the company also reported provisions for bad debts, a smaller order book, and said it won't pay a dividend due to its negative cash position.
-------
By James Kemp; jameskemp@alliancenews.com; @jamespkemp

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
26 Mar 2024 14:00

Scancell doses first patient in melanoma-focused trials

(Alliance News) - Scancell Holdings PLC announced on Tuesday that the first patient of a new trial cohort has been dosed with its iSCIB1+ therapeutic.

Read more
5 Feb 2024 14:09

TRADING UPDATES: Alliance Pharma appoints chair; FireAngel sales down

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
30 Jan 2024 13:56

Scancell interim loss narrows amid finance gain on derivative

(Alliance News) - Scancell Holdings PLC on Tuesday reported a narrowed loss as it gained on the revaluation of derivative liability.

Read more
17 Jan 2024 14:26

IN BRIEF: Scancell approved by MHRA to add new cohort to Scope trial

Scancell Holdings PLC - Oxford, England-based developer of immunotherapies for treatment of cancer and infectious disease said - Receives approval from UK's Medicines & Healthcare products Regulatory agency to add a third cohort to the Scope trial. Says the cohort will consist of 43 melanoma patients who will receive iSCIB1+ with doublet therapy, consisting of ipilimumab, under the brand name Yervoy, plus nivolumab, under the name Opdivo. "Exceptional" results from the first 13 patients receiving SCIB1 in the ongoing Scope trial, with an objective response rate of 85%, indicate a high probability of success in this cohort, which is expected to complete in the second quarter of 2024. Meanwhile, recruitment into the iSCIB1+ cohort is expected to be complete by the end of the second quarter as well, with early data expected in the third quarter of 2024.

Read more
19 Dec 2023 13:35

Scancell raises GBP12 million in total from fundraise

(Alliance News) - Scancell Holdings PLC on Tuesday said it has raised GBP11.9 million in total, from an open offer, placing, and subscription of shares.

Read more
1 Dec 2023 09:54

IN BRIEF: Scancell raises GBP10.7 million in upsized share sale

Scancell Holdings PLC - Oxford, England-based developer of immunotherapies for treatment of cancer and infectious disease - Raises GBP10.7 million from the placing and subscription of 97.0 million new shares at 11 pence each. The placing is run by Stifel Nicolaus Europe Ltd and WG Partners LLP. Scancell also plans an open offer of shares at the same price to raise up to another GBP2.0 million. Scancell says the placing was oversubscribed and upsized as a result. After the London market close on Thursday, Scancell had announced plans to raise just GBP6 million in the placing. It says the raise was led by "new institutional and life science specialist investors".

Read more
30 Nov 2023 21:10

EARNINGS AND TRADING: Dispensa and SkinBioTherapeutics losses widen

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
28 Nov 2023 14:57

TRADING UPDATES: Scancell trial progresses; OptiBiotix inks new deal

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
22 Nov 2023 15:53

UK shareholder meetings calendar - next 7 days

Thursday 23 November 
abrdn UK Smaller Companies Growth Trust PLCAGM
Avation PLCAGM
Bradda Head Lithium LtdAGM
DX Group PLCAGM
Europa Oil & Gas Holdings PLCAGM
Fiske PLCAGM
JPMorgan UK Smaller Cos Investment Trust PLCAGM
Hotel Chocolat Group PLCAGM
Pacific Horizon Investment Trust PLCAGM
Pan African Resources PLCAGM
PZ Cussons PLCAGM
Rosslyn Data Technologies PLCAGM
Friday 24 November 
Base Resources LtdAGM
Cloudbreak Discovery PLCAGM
Esken LtdEGM re Esken Renewables disposal
Neometals LtdAGM
Sovereign Metals LtdAGM
Sylvania Platinum LtdAGM
Monday 27 November 
Chelverton Growth Trust PLCGM re voluntary liquidation
European Smaller Cos Trust PLCAGM
JPMorgan Global Emerging Markets Income Trust PLCAGM
Quadrise PLCAGM
Tribal Group PLCGM re cash offer by Tiger Bidco 1 Ltd
Tuesday 28 November 
Bluefield Solar Income Fund LtdAGM
London Finance & Investment Group PLCAGM
Nanoco Group PLCAGM
Oakley Capital Investments LtdAGM
Wednesday 29 November 
Artemis Resources LtdAGM
Aura Energy LtdAGM
Contango Holdings PLCAGM
CVS Group PLCAGM
Fidelity Asian Values PLCAGM
Ikigai Ventures LtdAGM
Panthera Resources PLCAGM
Reconstruction Capital II LtdAGM
Renishaw PLCAGM
RiverFort Global Opportunities PLCAGM
Sabien Technology Group PLCAGM
Scancell Holdings PLCAGM
Seeing Machines LtdAGM
SLF Realisation Fund LtdAGM
Target Healthcare REIT PLCAGM
Thor Energy PLCAGM
Transense Technologies PLCAGM
Vast Resources PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
10 Nov 2023 11:14

IN BRIEF: Scancell shares up as presents "trailblazing" trial data

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Presents data from first stage of Phase 2 Scope trial at 20th International Congress of the Society for Melanoma Research on Thursday. Trial investigates Scancell's SCIB1 vaccination combined with checkpoint inhibitors in advanced melanoma. Company reported mid-September that SCIB1 combined with CPIs showed an 82% objective response rate. Scope trial is currently in its second stage. Scancell says on Friday that in Cohort 1 nine responses were achieved earlier than expected, and probability of second-stage success is around 90% based on current data.

Read more
31 Oct 2023 14:45

EARNINGS: Frontier IP chair to step down; "busy" Rosslyn narrows loss

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
20 Oct 2023 09:00

IN BRIEF: Scancell says needs more time to publish annual results

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says auditor request additional time to complete standard audit of its results of financial year 2023 that ended on April 30. Cites unforeseen circumstances impacting the audit engagement team. Says audit is substantially complete without any material audit issues.

Read more
17 Oct 2023 15:43

UK earnings, trading statements calendar - next 7 days

Wednesday 18 October 
888 Holdings PLCTrading Statement
Antofagasta PLCTrading Statement
BHP Group LtdTrading Statement
Cirata PLCTrading Statement
Hochschild Mining PLCTrading Statement
Liontrust Asset Management PLCTrading Statement
Quilter PLCTrading Statement
Segro PLCTrading Statement
Sosandar PLCTrading Statement
Whitbread PLCHalf Year Results
Thursday 19 October 
AJ Bell PLCTrading Statement
Centamin PLCQ3 Results
Deliveroo PLCTrading Statement
Dunelm Group PLCTrading Statement
GB Group PLCTrading Statement
Gear4Music PLCHalf Year Results
Hargreaves Lansdown PLCTrading Statement
London Stock Exchange Group PLCTrading Statement
Man Group PLCTrading Statement
Mondi PLCTrading Statement
PensionBee Group PLCTrading Statement
Rathbones Group PLCTrading Statement
Relx PLCTrading Statement
Rentokil Initial PLCQ3 Results
Sabre Insurance Group PLCTrading Statement
Schroders PLCTrading Statement
St James's Place PLCTrading Statement
Friday 20 October 
Foxtons Group PLCTrading Statement
InterContinental Hotels Group PLCTrading Statement
Record PLCTrading Statement
Monday 23 October 
Shanta Gold LtdTrading Statement
South32 LtdTrading Statement
Tuesday 24 October 
Angling Direct PLCHalf Year Results
Anglo American PLCTrading Statement
Barclays PLCQ3 Results
Bunzl PLCTrading Statement
FD Technologies PLCHalf Year Results
Gattaca PLCFull Year Results
Petra Diamonds LtdQ1 Results
Scancell Holdings PLCFull Year Results
Softcat PLCFull Year Results
Travis Perkins PLCTrading Statement
Trifast PLCTrading Statement
WAG Payment Solutions PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
22 Sep 2023 13:05

IN BRIEF: Oxford Technology 2 VCT asset value hurt by AIM share falls

Oxford Technology 2 VCT PLC - venture capital trust investing in quoted and unquoted technology companies - Net asset value of OT1 shares falls by 16% to 37.9 pence on August 31 from 45.3p on February 28. Similarly, NAV of OT2 shares falls to 20.5p from 25.1p, of OT3 shares to 23.6p from 33.7p, and of OT4 shares to 25.4p from 29.7p. No dividends are paid during the half year, nor are any shares bought back.

Read more
19 Sep 2023 14:32

Scancell celebrates "positive" clinical trial data for cancer vaccine

(Alliance News) - Scancell Holdings PLC shares surged on Tuesday after the company announced positive results from the phase 2 clinical trial of its SCIB1 treatment for advanced melanoma.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.